Rebleeding risk after treatment of XXXX .

@entity1 @entity510 @entity1756 @entity439 @entity438
OBJECT: Postprocedural rebleeding is a significant source of morbidity following endovascular treatment of @entity1756 . Previous large-scale reports include the @entity438 Rerupture After Treatment trial, the International @entity510 Trial, and the study on Early Rebleeding after Coiling of Ruptured @entity438 , which reported nonprocedural rebleeding rates within 30 days of treatment of 2.7%, 1.9%, and 1.4%, respectively. However, coiling of @entity438 is in a state of continual change due to advancing device design and evolving techniques. These studies included only @entity1 initially treated prior to 2004. In the present study the authors assess the most recent short-term results with endovascular treatment of @entity1756 . METHODS: A multicenter retrospective chart review was conducted of @entity1 undergoing endovascular treatment for @entity1756 between July 2004 and October 2009. The technique used, including the use of stent or balloon assistance, was evaluated. Demographic and clinical factors, such as sex, age, initial clinical presentation, @entity439 size, @entity439 location, and modified Raymond Classification following initial treatment, were also evaluated and compared between the groups in which rebleeding did and did not occur. RESULTS: A total of 469 @entity1 underwent endovascular treatment for a @entity1756 ; nonprocedural rehemorrhage occurred within 30 days of the initial coiling in 4 cases (0.9%). Two @entity1 (50%) died after rehemorrhage. Stent-assisted coiling was used during the original treatment in 1 (25%) of the 4 @entity1 with a rerupture. However, no technical, clinical, or demographic factors were found to be statistically significant in association with rebleeding. CONCLUSIONS: Recent data suggest that the periprocedural rebleeding rate may be improving over time.
